Physician profile
James H Lee
NPI 1396772372
$26,999.12
in general payments reported to CMS, 2019-2025
27 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,584 · 2020: $3,033 · 2021: $3,980 · 2022: $1,806 · 2023: $5,569 · 2024: $9,832 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $7,475 · Consulting Fee: $4,700 · Food and Beverage: $4,394 · Gift: $27.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $7,474.85 |
| Consulting Fee | $4,700.00 |
| Food and Beverage | $4,393.91 |
| Gift | $27.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $8,519.82 | 2019-2025 | Ce-Marked Kxla System, Photrexa, Kxl System (Not Refurbished) |
| Allergan, INC. | $6,777.75 | 2019-2022 | |
| Abbvie INC. | $6,319.08 | 2022-2025 | |
| Alcon Vision LLC | $3,598.12 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $380.61 | 2019-2023 | |
| Rxsight INC | $357.80 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $211.58 | 2019-2023 | Intralase Fs Femtosec Laser, Ifs Advanced Femtosec Laser |
| Eyepoint US, INC. | $157.98 | 2022 | |
| Oyster Point Pharma, INC. | $89.91 | 2023-2025 | Tyrvaya, Ryzumvi |
| Vantage Technology LLC | $81.02 | 2023-2025 | |
| Sight Sciences, INC. | $62.04 | 2022-2023 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $61.11 | 2021-2023 | Acthar |
| Ocular Therapeutix, INC. | $44.83 | 2020-2022 | |
| Genentech USA, INC. | $42.91 | 2024 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $41.31 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $32.92 | 2023 | Eylea |
| Biotissue Holdings INC. | $31.43 | 2021-2024 | |
| Nova Eye, INC. | $25.85 | 2024 | |
| Aerie Pharmaceuticals, INC. | $24.63 | 2020 | |
| Bausch & Lomb Americas INC. | $22.79 | 2025 | Vyzulta |
| Tarsus Pharmaceuticals, INC. | $21.86 | 2025 | Xdemvy |
| Astellas Pharma US INC | $19.84 | 2023 | |
| Optos, INC. | $18.50 | 2020 | |
| Ivantis, INC | $16.73 | 2021 | |
| Ani Pharmaceuticals, INC. | $16.52 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $13.31 | 2024 | Vevye |
| New World Medical,INC. | $8.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.